Lördag 29 Augusti | 07:22:39 Europe / Stockholm
Svenska | English
Investor Relations
Public Relations

All ägardata du vill ha finns i Holdings!

Lytix Biopharma (Q2 Review): FDA Clears Phase III Path for Ruxotemitide

2026-08-28 18:24:00

Redeye’s analyst just published a Research Update on Lytix Biopharma.
Click here to read the article
Make sure to add Lytix Biopharma to your Watchlist at Redeye and our analysts will notify you if anything relevant happens regarding your companies.

About Redeye Nordic Growth AB

This is a press release from Redeye Nordic Growth AB, a equity research firm specializing in Nordic growth companies within Tech and Life Science. Redeye Nordic Growth is a part of the Redeye group, which also offers services within corporate finance advisory and fund management. https://services.redeye.se/

Attachments

Lytix Biopharma (Q2 Review): FDA Clears Phase III Path for Ruxotemitide

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Företag
Pressmeddelanden